Treatment of Inflammatory Bowel Disease with Biologics

Treatment of In ammatory Bowel Disease with Biologics Adam S. Cheifetz Joseph D. Feuerstein Editors 123 ...

Treatment of Inflammatory Bowel Disease with Biologics ...

Adam S. Cheifetz • Joseph D. Feuerstein Editors Treatment of Inflammatory Bowel Disease with Biologics ...

ISBN 978-3-319-60275-2 ISBN 978-3-319-60276-9 (eBook) https://doi.org/10.1007/978-3-319-60276- Library of Congress Control Numbe ...

v Preface In the last number of years, the treatments for inflammatory bowel disease have been rapidly evolving. With the emerge ...

vi We believe that this book will provide the reader with a thorough review of bio- logic therapies in inflammatory bowel diseas ...

vii 1 Mechanism of Action and Pharmacokinetics of Biologics.......... 1 Alan C. Moss 2 Antitumor Necrosis Factor Agents in Ulcer ...

viii 11 Biologic Therapy in Pediatric Inflammatory Bowel Disease........ 163 Sonal Patel and Jennifer Strople 12 Infectious Comp ...

ix Contributors Renée  M.  Marchioni  Beery Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospita ...

x Sunanda V. Kane Mayo Clinic, Rochester, MN, USA Asher Kornbluth Henry Janowitz Division of Gastroenterology, Icahn School of M ...

xi Corey  A.  Siegel Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmout ...

© Springer International Publishing AG 2018 1 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease wit ...

2 T lymphocytes, monocytes/macrophages, and natural killer (NK) cells but also non- immune cells such as endothelial cells and f ...

3 TNF binding to their reference products [ 7 ]. Regardless of the extent of TNF bind- ing, this step prevents TNF from binding ...

4 Pharmacokinetics of Anti-TNFs Pharmacokinetics (pK) describes the effects of the body’s physiological processes on an administ ...

5 of this book. For many drugs, response is dependent on drug concentrations or drug exposure (the AUC), and therefore drug conc ...

6 In addition to its effects on effector (pro-inflammatory) T-cells (Teff), β7 integrin is a component of migration of regulator ...

7 by inducing lymphokine-activated killer cells and activation of natural killer (NK) cells and T lymphocytes, particularly Th1 ...

8 approximately 57%, the volume of distribution of ustekinumab is approximately 8.9 L, consistent with confinement to the circul ...

9 Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and comple- ment activation of adalimumab, i ...